Literature DB >> 12517781

Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.

Fang-Xian Sun1, Akiko Tohgo, Michael Bouvet, Shigeo Yagi, Rounak Nassirpour, Abdoul R Moossa, Robert M Hoffman.   

Abstract

We determined the antitumor and antimetastatic efficacy of the camptothecin analogue DX-8951f in an orthotopic metastatic mouse model of pancreatic cancer. DX-8951f showed efficacy against two human pancreatic tumor cell lines in this model. These cell lines were transduced with the green fluorescent protein, enabling high-resolution visualization of tumor and metastatic growth in vivo. The DX-8951f studies included both an early and advanced cancer model. In the early model, using the human pancreatic cancer lines MIA-PaCa-2 and BxPC-3, treatment began when the orthotopic primary tumor was approximately 7 mm in diameter. DX-8951f was significantly effective against both MIA-PaCa-2 and BxPC-3. In contrast, 2', 2'-difluorodeoxycytidine (gemcitabine), the standard treatment for pancreatic cancer, did not have significant efficacy against MIA-PaCa-2. Although gemcitabine showed significant activity against BxPC-3 primary tumor growth, it was not effective on metastasis. In the model of advanced disease, using BxPC-3, treatment started when the orthotopic primary tumor was 13 mm in diameter. DX-8951f was significantly effective in a dose-response manner on the BxPC-3 primary tumor. DX-8951f also demonstrated antimetastatic activity in the late-stage model, significantly reducing the incidence of lymph node metastasis while eliminating lung metastasis. In contrast, gemcitabine was only moderately effective against the primary tumor and ineffective against metastasis at both sites in the late-stage model. Therefore, DX-8951f was highly effective against primary and metastatic growth in this very difficult-to-treat disease and showed significantly higher efficacy than gemcitabine, the standard treatment of pancreatic cancer. DX-8951f, therefore, has important clinical promise and has more positive features than the currently used camptothecin analogue CPT-11, which requires metabolic activation and is toxic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517781

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Down-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells.

Authors:  Lu Kong; Zhihong Deng; Yanzhong Zhao; Yamei Wang; Fazlul H Sarkar; Yuxiang Zhang
Journal:  Med Oncol       Date:  2010-06-08       Impact factor: 3.064

Review 2.  Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Authors:  Jie-Er Ying; Li-Ming Zhu; Bi-Xia Liu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

3.  EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.

Authors:  Goutam Mondal; Virender Kumar; Surendra K Shukla; Pankaj K Singh; Ram I Mahato
Journal:  Biomacromolecules       Date:  2015-12-17       Impact factor: 6.988

4.  LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.

Authors:  Rene Hennig; Jacinthe Ventura; Ralf Segersvard; Erin Ward; Xian-Zhong Ding; Sambasiva M Rao; Borko D Jovanovic; Takeshi Iwamura; Mark S Talamonti; Richard H Bell; Thomas E Adrian
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

5.  Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis.

Authors:  Haizhou Liu; John C Schmitz; Jianteng Wei; Shousong Cao; Jan H Beumer; Sandra Strychor; Linyou Cheng; Ming Liu; Cuicui Wang; Ning Wu; Xiangzhong Zhao; Yuyan Zhang; Joshua Liao; Edward Chu; Xiukun Lin
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

6.  Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT-2 pancreatic cancer mouse model.

Authors:  Tamami Higuchi; Takehiko Yokobori; Tomoharu Naito; Chihaya Kakinuma; Shinji Hagiwara; Masahiko Nishiyama; Takayuki Asao
Journal:  Oncol Lett       Date:  2017-12-29       Impact factor: 2.967

7.  Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer.

Authors:  Mark S Duxbury; Evan Matros; Hiromichi Ito; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

8.  Dual-color fluorescence imaging in a nude mouse orthotopic glioma model.

Authors:  Xuepeng Zhang; Xuguang Zheng; Feng Jiang; Zheng Gang Zhang; Mark Katakowski; Michael Chopp
Journal:  J Neurosci Methods       Date:  2009-05-15       Impact factor: 2.390

9.  Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model.

Authors:  Xian-Ping Liu; Sheng-Tao Zhou; Xing-Yi Li; Xian-Cheng Chen; Xia Zhao; Zhi-Yong Qian; Li-Na Zhou; Zhi-Yong Li; Yu-Mei Wang; Qian Zhong; Tao Yi; Zheng-Yu Li; Xiang He; Yu-Quan Wei
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

10.  A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.

Authors:  Rohit Chugh; Veena Sangwan; Satish P Patil; Vikas Dudeja; Rajinder K Dawra; Sulagna Banerjee; Robert J Schumacher; Bruce R Blazar; Gunda I Georg; Selwyn M Vickers; Ashok K Saluja
Journal:  Sci Transl Med       Date:  2012-10-17       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.